Clinical trials: Refractory Active Systemic Lupus Erythematosus

Systemic Lupus Erthematosus (SLE)

KN5501 Cell Injection for Refractory SLE(CLEAR)

• Not yet recruiting
• Age: 18 to 70 years
• Phase 1
• Injection or infusion

The goal of this clinical trial is to learn about the safety, pharmacokinetics and pharmacodynamics profile of KN5501 cell injection in adults with systemic lupus erythematosus(SLE).

Trial name

CLEAR (NCT07358988)

Testing

KN5501 cell injection

Where

6 sites in China

Volunteers

36 people

Sponsor

Ruitherapeutics Co., LTD